Navigation Links
BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Date:8/13/2008

at NCI.

- NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.

- According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the anti-cancer drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.

Dr. Jeffrey Schlom is the principal investigator at the NCI for this CRADA and is Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH. Dr. Schlom is one of the leading figures in the area of cancer vaccine development, and has been improving and refining novel immunotherapeutic approaches for cancer in clinical studies for more than 10 years. The collaborative effort between BN ImmunoTherapeutics and NCI will hopefully provide urgently needed new therapies for patients suffering from prostate cancer.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The NCI relationship opens up for us new and exciting opportunities within the field of cancer and we are proud to join forces with one of the most prestigious and well-established cancer research organisations in the world. In the collaboration with NCI, BN ImmunoTherapeutics benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organisation."

Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark. BN ImmunoTherapeutics is developing immune based therapies for breast and prostate cancer.

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology, MVA-BN(R), has been demonstrated
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... 2009 First Quarter Highlights , , , ... million in the first quarter of 2008 , ... first quarter of 2008 , Saflex ... The Company,s cash generation in the quarter allowed for debt ...
... 6 ChanTest, the leading expert in ion channels ... discovery, development, and safety -- is one of eight ... Research and Commercialization Program. Governor Ted Strickland and Interim ... of the Ohio Third Frontier Commission, Mark Barbash, announced ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
Cached Biology Technology:Solutia Reports First Quarter 2009 Results 2Solutia Reports First Quarter 2009 Results 3Solutia Reports First Quarter 2009 Results 4Solutia Reports First Quarter 2009 Results 5Solutia Reports First Quarter 2009 Results 6Solutia Reports First Quarter 2009 Results 7Solutia Reports First Quarter 2009 Results 8Solutia Reports First Quarter 2009 Results 9Solutia Reports First Quarter 2009 Results 10Solutia Reports First Quarter 2009 Results 11Solutia Reports First Quarter 2009 Results 12Solutia Reports First Quarter 2009 Results 13Solutia Reports First Quarter 2009 Results 14Solutia Reports First Quarter 2009 Results 15Solutia Reports First Quarter 2009 Results 16Solutia Reports First Quarter 2009 Results 17Solutia Reports First Quarter 2009 Results 18Solutia Reports First Quarter 2009 Results 19Solutia Reports First Quarter 2009 Results 20Solutia Reports First Quarter 2009 Results 21ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... Clemson professor Rajendra Singh Thursday as a "Champion ... expand solar deployment in the residential, commercial and ... Professor of Electrical and Computer Engineering and director ... a local hero leading the charge across the ... solar power and driving policy changes at the ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... Center have discovered a basic mechanism by which smooth ... ?sometimes abnormally ?suggesting methods of treatment for various coronary ... involved in hypertension, coronary artery disease, tumors called leiosarcomas ... it is now possible to begin to design therapies ...
... different rates, and the evolutionary line that produced humans seems ... new study by scientists at the European Molecular Biology Laboratory ... very ancient ancestor that have been lost in more quickly-evolving ... genes in the first animals. The work appears in the ...
... warblers and beaver dams once were bountiful in an area ... left this area, elk grew more plentiful, browsing heavily on ... sparrows have replaced the warblers in what is now a ... of the wolf, a top predator. That's the compelling finding ...
Cached Biology News:UT Southwestern researchers unravel control of growing blood vessels 2The earliest animals had human-like genes 2The earliest animals had human-like genes 3Wolves' top-down effect 2